NRX Pharmaceuticals Files 8-K
Ticker: NRXPW · Form: 8-K · Filed: Aug 15, 2025 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, regulatory-filing
Related Tickers: NRXP
TL;DR
NRXP filed an 8-K on 8/15 for 8/11 events - mostly financial docs.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on August 15, 2025, reporting on events that occurred on August 11, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text beyond the standard reporting requirements.
Why It Matters
This filing indicates NRX Pharmaceuticals is meeting its regulatory reporting obligations. Investors should review the full document for details on financial statements and exhibits.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- August 11, 2025 (date) — Earliest event reported
- August 15, 2025 (date) — Filing date
- Delaware (location) — State of incorporation
- 1201 Orange Street, Suite 600 Wilmington, Delaware 19801 (address) — Business and mailing address
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The filing indicates that 'Financial Statements and Exhibits' are being reported, but the specific details of these documents are not provided in the excerpt.
What is the significance of the 'Other Events' item information?
The 'Other Events' item information is listed, but the excerpt does not detail what these events are.
When was NRX Pharmaceuticals, Inc. incorporated?
NRX Pharmaceuticals, Inc. was incorporated in Delaware.
What is the Commission File Number for NRX Pharmaceuticals, Inc.?
The Commission File Number for NRX Pharmaceuticals, Inc. is 001-38302.
What was the former name of NRX Pharmaceuticals, Inc.?
The former name of NRX Pharmaceuticals, Inc. was Big Rock Partners Acquisition Corp., with a name change date of October 12, 2017.
Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-08-14 21:47:31
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 pershare NRXP The Nasdaq Stock Mark
Filing Documents
- nrxp20250814_8k.htm (8-K) — 28KB
- ex_853338.htm (EX-99.1) — 24KB
- logo.jpg (GRAPHIC) — 2KB
- 0001437749-25-027059.txt ( ) — 210KB
- nrxp-20250811.xsd (EX-101.SCH) — 4KB
- nrxp-20250811_def.xml (EX-101.DEF) — 14KB
- nrxp-20250811_lab.xml (EX-101.LAB) — 18KB
- nrxp-20250811_pre.xml (EX-101.PRE) — 14KB
- nrxp20250814_8k_htm.xml (XML) — 5KB
01
Item 8.01 Other Events On August 11, 2025, NRx Pharmaceuticals, Inc. issued a press release announcing that the United States Food and Drug Administration has granted Fast Track designation to NRX-100, the Company's formulation of ketamine for intravenous infusion, for the treatment of suicidal ideation in patients with depression, including bipolar depression. A copy of the press release is attached hereto as Exhibit 99.1. On August 13, 2025, NRx Pharmaceuticals received a letter from the FDA in response to the Company's Abbreviated New Drug Approval (ANDA) application for NRX-100. The letter identified missing manufacturing batch records and a 6% quantitative difference in one inactive ingredient as deficiencies to be remedied in order for FDA to receive the ANDA filing. Although a number of minor administrative deficiencies were also identified, no other scientific impediments were noted. The Company will supply the missing batch records, adjust its formulation as needed with respect to this single ingredient and resubmit the ANDA in cooperation with FDA. Management believes that the guidance received by the FDA is a routine part of the regulatory process and will not result in any undue delay.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release, dated August 11, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: August 15, 2025 By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Interim Chief Executive Officer